

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux et al.

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: Herewith

Examiner: To be assigned

For: APOLIPOPROTEIN A-I AGONISTS  
AND THEIR USE TO TREAT  
DYSLIPIDEMIC DISORDERS

Attorney Docket No.: 9196-022-999



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

- 1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.
- 1b. A legible copy of :
  - ☐ Each U.S. patent application publication and U.S. and foreign patent;
  - ☐ Each publication or that portion which caused it to be listed on the PTO-1449;
  - ☐ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
  - ☐ all other information or portion which caused it to be listed on the PTO-1449.
- 1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

- 1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
2. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
- ☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
  - ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
  - ☒ Before the mailing of the first Office action on the merits;
  - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

*(Check either Item 3a or 3b)*

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- ☐ enclosed
  - ☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

*(Item 3b to be checked if any reference known for more than 3 months)*

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
- ☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

The Certification Statement in Item 5 below is applicable.

5. ☐ Certification Statement *(applicable if Item 3a or Item 4 is checked)*

*(Check either Item 5a or 5b)*

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

- 5b. ☐ In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

6. ☒ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

*(Check appropriate Items 6a, 6b and/or 6c)*

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.

- 6b. ☒ Copies of publications listed on Form PTO-1449 from prior application Serial No. 09/453,834, filed on December 1, 1999, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).

- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No.         , filed on         , and are provided herewith.

7. ☐ This is a Supplemental Information Disclosure Statement. *(Check either Item 7a or 7b)*

- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on         . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on         .

- 7b. ☐ This Supplemental Information Disclosure Statement is timely filed within one (1) month of a PTO Notice under 37 C.F.R. §1.97(i).

8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

*( Check Item 8a, 8b, or 8c)*

- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.

- 8b. ☐ set forth in the application.


- 8c. ☐ enclosed as an attachment hereto.

9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150.

10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date March 15, 2002

  
Rahul Pathak 42,983  
(Reg. No.)

For: Laura A. Coruzzi (Reg No. 30,742)

PENNIE & EDMONDS L.L.P.  
1155 Avenue of Americas  
New York NY 10036-2720  
(212) 790 - 9090

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

9196-022-999

APPLICATION NO.

To be assigned

APPLICANT

Dasseux *et al.*

FILING DATE

Herewith

GROUP

To be assigned

U.S. PAT. & TM. OFF.  
10/099836  
03/15/02

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,229,360	10/21/80	Schneider <i>et al.</i>			
	AB	4,411,894	10/25/83	Schrank <i>et al.</i>			
	AC	4,643,998	02/17/87	Segrest <i>et al.</i>			
	AD	4,857,319	08/15/89	Crowe <i>et al.</i>			
	AE	4,880,635	11/14/89	Janoff <i>et al.</i>			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AF	WO 93/25581	12/23/93	PCT				
	AG	WO 94/13819	06/23/94	PCT				
	AH	WO 96/04916	02/22/96	PCT				
	AI	WO 96/37608	11/28/96	PCT				
	AJ	0 162 414	05/15/85	EPO				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK	Anantharamaiah, 1986, <u>Methods in Enzymology</u> 128:627-647
	AL	Anantharamaiah <i>et al.</i> , 1985, <u>J. Biol. Chem.</u> 260:10248-10255
	AM	Anantharamaiah <i>et al.</i> , 1986, <u>Proteins of Biological Fluids</u> 34:63-66
	AN	Anantharamaiah <i>et al.</i> , 1990, <u>Arteriosclerosis</u> 10(1):95-105
	AO	Anantharamaiah <i>et al.</i> , 1991, <u>Adv. Exp. Med. Biol.</u> 285:131-140
	AP	Badimon <i>et al.</i> , 1990, <u>J. Clin. Invest.</u> 85:1234-1241
	AQ	Barrans <i>et al.</i> , 1996, <u>Biochim. Biophys. Acta</u> 1300:73-85
	AR	Beitz <i>et al.</i> , 1992, <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> 47:149-152
	AS	Berard <i>et al.</i> , 1997, <u>Nature Medicine</u> 3(7):744-749
	AT	Blondelle <i>et al.</i> , 1993, <u>Biochim. Biophys. Acta</u> 1202:331-336
	AU	Brasseur, 1991, <u>J. Biol. Chem.</u> 266(24):16120-16127
	AV	Brasseur <i>et al.</i> , 1990, <u>Biochim. Biophys. Acta</u> 1043:245-252
	AW	Brasseur <i>et al.</i> , 1993, <u>Biochim. Biophys. Acta</u> 1170:1-7
	AX	Brouillette and Anantharamaiah, 1995, <u>Biochim. Biophys. Acta</u> 1256:103-129
	AY	Burkey <i>et al.</i> , 1992, <u>Circulation, Supplement I</u> 86:I-472, Abstract No. 1876
	AZ	Burkey <i>et al.</i> , 1995, <u>J. Lipid Res.</u> 36:1463-1473
	BA	Cheung <i>et al.</i> , 1991, <u>Lipid Res.</u> 32:383-394

BB	Chung <i>et al.</i> , 1985, <i>J. Biol. Chem.</i> 260:10256-10262
BC	Collet <i>et al.</i> , 1997, <i>Journal of Lipid Research</i> 38:634-644
BD	Corijn <i>et al.</i> , 1993, <i>Biochim. Biophys. Acta</i> 1170:8-16
BE	Davidson <i>et al.</i> , 1994, <i>J. Biol. Chem.</i> 269(37):22975-22982
BF	Davidson <i>et al.</i> , 1996, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93:13605-13610
BG	Deamer <i>et al.</i> , 1983, <i>Liposomes</i> (Ostro, Ed.), Marcel Dekker, Inc., New York
BH	Demoor <i>et al.</i> , 1996, 24th European Chemical Peptide Symposium
BI	Demoor <i>et al.</i> , 1996, <i>Eur. J. Biochem.</i> 239:74-84
BJ	Dufourcq <i>et al.</i> , 1986, <i>Biochim. Biophys. Acta</i> 859:33-48
BK	Duverger, 1996, <i>Circulation</i> 94:713-717
BL	Duverger <i>et al.</i> , 1996, <i>Arterioscler. Thromb. Vasc. Biol.</i> 16:1424-1429
BM	Emmanuel <i>et al.</i> , 1994, <i>J. Biol. Chem.</i> 269(47):29883-29890
BN	Epand <i>et al.</i> , 1987, <i>J. Biol. Chem.</i> 262:9389-9396
BO	Epand <i>et al.</i> , 1995, <i>Biopolymers (Peptide Science)</i> 37:319-338
BP	Esposito <i>et al.</i> , 1997, <i>Biopolymers</i> 41:27-35
BQ	Fielding and Fielding, 1995, <i>J. Lipid Res.</i> 36:211-228
BR	Fournier <i>et al.</i> , 1996, <i>J. Lipid Res.</i> 37:1704-1711
BS	Francone <i>et al.</i> , 1995, <i>J. Clin. Invest.</i> 96:1440-1448
BT	Frank <i>et al.</i> , 1997, <i>Biochemistry</i> 36:1789-1806
BU	Fruchart and Ailhaud, 1992, <i>Clin. Chem.</i> 38:793-797
BV	Fukushima <i>et al.</i> , 1979, <i>J. Am. Chem. Soc.</i> 101(13):3703-3704
BW	Fukushima <i>et al.</i> , 1980, <i>J. Biol. Chem.</i> 255:10651-10657
BX	Garber <i>et al.</i> , 1992, <i>Arteriosclerosis and Thrombosis</i> 12:886-894
BY	Gordon <i>et al.</i> , 1989, <i>Circulation</i> 79:8-15
BZ	Gordon and Rifkind, 1989, <i>N. Eng. J. Med.</i> 321:1311-1316
CA	Groebeke <i>et al.</i> , 1996, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93:4025-4029
CB	Hirano <i>et al.</i> , 1997, <i>Arterioscler. Thromb. Vasc. Biol.</i> 17(6):1053-1059
CC	Holvoet <i>et al.</i> , 1995, <i>Biochemistry</i> 34:13334-13342
CD	Hope <i>et al.</i> , 1986, <i>Chemistry and Physics of Lipids</i> 40:89-107
CE	Huyghues-Despointes <i>et al.</i> , 1995, <i>Biochemistry</i> 34(41):13267-13271
CF	Ji and Jonas, 1995, <i>J. Biol. Chem.</i> 270:11290-11297
CG	Johnson <i>et al.</i> , 1971, <i>Biochim. Biophys. Acta</i> 233:820
CH	Jonas, 1986, <i>Methods in Enzymol.</i> 128:553-582
CI	Jonas, 1992, "Lipid-Binding Properties of Apolipoproteins," <i>In: Structure and Function of Apolipoproteins</i> , CRC Press, Ch. 8, pp. 217-250
CJ	Kaiser, 1970, <i>Anal. Biochem.</i> 34:595-598
CK	Kaiser and Kezdy, 1983, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 80:1137-1143
CL	Kannelis <i>et al.</i> , 1980, <i>J. Biol. Chem.</i> 255(3):11464-11472
CM	Koizumi <i>et al.</i> , 1988, <i>J. Lipid Res.</i> 29:1405-1415
CN	Kneib-Cordonnier <i>et al.</i> , 1990, <i>Int. J. Peptide Protein Res.</i> 35:527-538

CO	Knott <i>et al.</i> , 1985, <i>Science</i> 230:37-43
CP	Labeur <i>et al.</i> , 1997, <i>Arterioscler. Throm. Vasc. Biol.</i> 17:580-588
CQ	Lacko and Miller, 1997, <i>J. Lip. Res.</i> 38:1267-1273
CR	Li <i>et al.</i> , 1996, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93:6676-6681
CS	Lins <i>et al.</i> , 1993, <i>Biochim. Biophys. Acta Biomembranes</i> 1151:137-142
CT	Liu <i>et al.</i> , 1994, <i>J. Lipid Res.</i> 35:2263-2267
CU	Livingstone, 1974, <i>Methods in Enzymology: Immunoaffinity Chromatography of Proteins</i> 34:723-731
CV	Lund-Katz <i>et al.</i> , 1990, <i>J. Biol. Chem.</i> 265(21):12217-12223
CW	Lund-Katz <i>et al.</i> , 1995, <i>Biochemistry</i> 34:9219-9226
CX	Marqusee <i>et al.</i> , 1987, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 84(24):8898-8902
CY	Mendez <i>et al.</i> , 1994, <i>J. Clin. Invest.</i> 94:1698-1705
CZ	Mezdour <i>et al.</i> , 1995, <i>Atherosclerosis</i> 113:237-246
DA	Miller, 1987, <i>Amer. Heart</i> 113:589-597
DB	Milner-White and Poet, 1987, <i>Trends Biochem. Sci.</i> 12:189-192
DC	Minnich <i>et al.</i> , 1992, <i>J. Biol. Chem.</i> 267:16553-16560
DD	Mishra <i>et al.</i> , 1994, <i>J. Biol. Chem.</i> 269(10):7185-7191
DE	Mishra <i>et al.</i> , 1995, <i>J. Biol. Chem.</i> 270(4):1602-1611
DF	Nakagawa <i>et al.</i> , 1985, <i>J. Am. Chem. Soc.</i> 107:7087-7092
DG	Nedelec <i>et al.</i> , 1989, <i>Biochimie</i> 71:145-151
DH	Palgunachari <i>et al.</i> , 1996, <i>Arterioscler. Thromb. Vasc. Biol.</i> 16:328-338
DI	Paszy <i>et al.</i> , 1994, <i>J. Clin. Invest.</i> 94:899-903
DJ	Plump <i>et al.</i> , 1994, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91:9607-9611
DK	Ponsin <i>et al.</i> , 1984, <i>Biochemistry</i> 23:5337-5342
DL	Ponsin <i>et al.</i> , 1986, <i>J. Biol. Chem.</i> 261(20):9202-9205
DM	Pownall <i>et al.</i> , 1980, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 77(6):3154-3158
DN	Rogers <i>et al.</i> , 1997, <i>Biochemistry</i> 36:288-300
DO	Rosseneu <i>et al.</i> , <i>In: Structure and Function of the Lipoproteins</i> , Ch. 6, 159-183, CRC Press, Inc., 1992
DP	Rosseneu and Labeur, 1995, <i>FASEB J.</i> 9:768-776
DQ	Rubin <i>et al.</i> , 1991, <i>Nature</i> 353:265-267
DR	Schnölzer and Kent, 1992, <i>Science</i> 256:221-225
DS	Schultz <i>et al.</i> , 1993, <i>Nature</i> 365:762-764
DT	Segrest, 1974, <i>FEBS Lett.</i> 38:247-253
DU	Segrest, 1976, <i>FEBS Lett.</i> 69(1):111-114
DV	Segrest <i>et al.</i> , 1983, <i>J. Biol. Chem.</i> 258:2290-2295
DW	Segrest <i>et al.</i> , 1990, <i>PROTEINS: Structure, Function and Genetics</i> 8:103-117
DX	Segrest <i>et al.</i> , 1992, <i>J. Lipid Res.</i> 33:141-166
DY	Segrest <i>et al.</i> , 1994, <i>Advances in Protein Chemistry</i> 45:303-369
DZ	Sorci-Thomas <i>et al.</i> , 1993, <i>J. Biol. Chem.</i> 268:21403-21409
EA	Sorci-Thomas <i>et al.</i> , 1997, <i>J. Biol. Chem.</i> 272(11):7278-7284

	EB	Sparks <i>et al.</i> , 1995, <i>J. Biol. Chem.</i> 270(10):5151-5157
	EC	Sparrow and Gotto, 1980, <i>Ann. N.Y. Acad. Sci.</i> 348:187-211
	ED	Sparrow and Gotto, 1982, <i>CRC Crit. Rev. Biochem.</i> 13:87-107
	EE	Sparrow and Gotto, Ch. 10: "Lipid-Protein Interactions: Structure-Function Relationships".
	EF	Sparrow <i>et al.</i> , 1981, <i>In</i> : "Peptides: Synthesis-Structure-Function," Roch and Gross, Eds., Pierce Chem. Co., Rockford, IL, 253-256
	EG	Spuhler <i>et al.</i> , 1994, <i>J. Biol. Chem.</i> 269(39):23904-23910
	EH	Subbarao <i>et al.</i> , 1988, <i>PROTEINS: Structure, Function and Genetics</i> 3:187-198
	EI	Tam, 1988, <i>Proc. Natl. Acad. Sci. U.S.A.</i> 85:5409-5413
	EJ	Tytler <i>et al.</i> , 1993, <i>J. Biol. Chem.</i> 268(29):22112-22118
	EK	Vanloo <i>et al.</i> , 1992, <i>Biochim. Biophys. Acta</i> 1128:258-266
	EL	Venkatachalapathi <i>et al.</i> , 1991, <i>Mol. Conformation and Biol. Interactions</i> , <i>Indian Acad. Sci. B</i> :585-596
	EM	Venkatachalapathi <i>et al.</i> , 1993, <i>PROTEINS: Structure, Function and Genetics</i> 15:349-359
	EN	Wang <i>et al.</i> , 1996, <i>Biochim. Biophys. Acta</i> 1301:174-184
	EO	Wilmot and Thornton, 1988, <i>J. Mol. Biol.</i> 203:221-232
	EP	Yancey <i>et al.</i> , 1995, <i>Biochemistry</i> 34:7955-7965
	EQ	Yokoyama <i>et al.</i> , 1980, <i>J. Biol. Chem.</i> 255(15):7333-7339

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with <b>MPEP 609</b> ; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	